Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488814 | 1.00 | KDM4E (0.43) | KDM4ETDP1LMNAHTTMAPT | |
| SCHEMBL29475148 | 0.80 | KDM4E (0.44) | KDM4ETDP1LMNAHTTMAPT | |
| SCHEMBL1489277 | 0.80 | KDM4E (0.44) | KDM4ETDP1LMNAHTTMAPT | |
| SCHEMBL9682539 | 0.79 | KDM4E (0.41) | KDM4ETDP1LMNAHTTMAPT | |
| SCHEMBL3219267 | 0.78 | LMNA (0.40) | KDM4ETDP1LMNAHTTRECQL | |
| SCHEMBL4833163 | 0.78 | TDP1 (0.43) | KDM4ETDP1LMNAHTTMAPT | |
| Zinc Ion SCHEMBL9440226 | 0.78 | KDM4E (0.43) | KDM4ETDP1LMNAHTTMAPT | |
| SCHEMBL2274172 | 0.78 | KDM4E (0.43) | KDM4ETDP1LMNAHTTMAPT | |
| Hydrochloric Acid SCHEMBL17984647 | 0.77 | BLM (0.41) | KDM4ETDP1LMNAHTTRECQL | |
| SCHEMBL7576244 | 0.76 | MAPT (0.41) | KDM4ETDP1LMNAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1580188-B9 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-23 | — | — | EP | claimed |
| JP-2005523278-A | — | — | 2005-08-04 | — | — | JP | claimed |
| EP-1474393-A1 | ARYL UREAS AS KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-11-10 | — | — | EP | claimed |
| WO-2003068746-A1 | ARYL UREAS AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3880182-A1 | IMPROVED AGGREGATED MICROPARTICLES | Graybug Vision, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-107108568-B | Pesticidally active amide heterocyclic derivatives with sulphur containing substituents | 先正达参股股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| WO-2020102758-A1 | IMPROVED AGGREGATED MICROPARTICLES | Graybug Vision, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| EP-3645001-A1 | MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF | G1 Therapeutics, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| CN-106458909-B | Insecticidal amide derivatives with sulfur-substituted phenyl or pyridine groups | 先正达参股股份有限公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-109641874-A | C for target protein degradation3The glutarimide degron body of carbon connection | C4医药公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109562107-A | Heterocyclic degrading ligand for target protein degradation | C4医药公司 | 2019-04-02 | — | — | CN | disclosed |
| US-6452008-B2 | 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| CN-1358173-A | Heterocyclic dicarboxylic acid diamide derivatives, agricultural and horticultural insecticides and method for using the same | NIHON NOHYAKU CO LTD (JP) | 2002-07-10 | — | — | CN | disclosed |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2001-12-13 | — | — | US | disclosed |
| US-6300500-B1 | Preparation of pyridone derivatives using phthalimido containing starting material | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1086948-A1 | PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-0327052-A2 | Use of quinoline derivatives for making a medicament effective in the prevention and treatment of ulcers | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4831040-A | (IMIDAZOLO-, THIAZOLO-, OXAZOLO-)(4,5-H)-QUINOLINE | RORER PHARMACEUTICAL CORPORATION (US) | 1989-05-16 | — | — | US | disclosed |
| US-4678794-A | N-pyridyl-substituted pyridine-2-carboxamide-1-oxides | JOHN WYETH & BROTHER LIMITED (GB) | 1987-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | HK1, HPD, ALK | KDM4E 139/4885TDP1 1024/4885LMNA 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.